Expertise in
1
conditions

Chengzhi Y. Lu

No. 24, Fukang Road, 
Tianjin, CN 
Expertise in
1
conditions
No. 24, Fukang Road, 
Tianjin, CN 

Overview

Chengzhi Lu practices practicing medicine in Tianjin, China.

Lu is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Renovascular Hypertension, Biliary Hypoplasia, Cerebral Hypoxia, Percutaneous Coronary Intervention (PCI), and Stent Placement.

They are actively involved in clinical research, co-authoring 96 peer reviewed articles and participating in 2 clinical trials.

Locations

No. 24, Fukang Road, Tianjin, 300192, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multi-center, Randomized, Double-blined, Placebo Parallel Controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Mortality of Subjects With Chronic Systolic Heart Failure on Standard HF Therapy.
A Multi-center, Randomized, Double-blined, Placebo Parallel Controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Mortality of Subjects With Chronic Systolic Heart Failure on Standard HF Therapy.
Enrollment Status: Unknown
Publish Date: February 01, 2024
Intervention Type: Drug
Study Drug: rhNRG-1
Study Phase: Phase 3
A Prospective, Multicenter, Single Blind, Randomized and Sham Controlled Trial of Renal Sympathetic Denervation Using SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator for the Treatment of Hypertension (SMART Trial)
A Prospective, Multicenter, Single Blind, Randomized and Sham Controlled Trial of Renal Sympathetic Denervation Using SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator for the Treatment of Hypertension (SMART Trial)
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2023
Intervention Type: Device
Study Phase: Not Applicable
View 1 Less Clinical Trial

96 Total Publications

TIF1β Promotes Myocardial Ischemia-Reperfusion Injury by Stabilizing TRAF6 through Mediating TRAF6 SUMOylation.
TIF1β Promotes Myocardial Ischemia-Reperfusion Injury by Stabilizing TRAF6 through Mediating TRAF6 SUMOylation.
Journal: International heart journal
Published: May 31, 2026

Frequently Asked Questions about Chengzhi Y. Lu

Is Chengzhi Y. Lu a top-rated expert for Renovascular Hypertension?

MediFind is an objective health platform that identifies experts based on real-world data. Chengzhi Y. Lu is classified as an Advanced expert for Renovascular Hypertension, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Chengzhi Y. Lu participate in research or clinical trials?

Yes. Chengzhi Y. Lu has published 96 articles and abstracts on conditions like Renovascular Hypertension. You can view a list of Chengzhi Y. Lu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Lu's expertise for a condition
ConditionClose
      View All 23 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile